Displaying drugs 1501 - 1525 of 2271 in total
CD-16 NK-92 cells
Investigational
PVX-410 component XBP1 US184-192(YISPWILAV)
Investigational
Anetumab ravtansine
Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
Investigational
Fluprednidene acetate
Fluprednidene acetate is a corticosteroid. It has anti-inflammatory and anti-allergic properties.
Experimental
Isoflupredone acetate
Vet approved
Aphidicolin
Aphidicolin is an antimitotic and antiviral metabolite of the mould Cephalosporium aphidicola. It inhibits DNA polymerase alpha and blocks DNA replication.[A259157, A259162]
Investigational
Afimetoran
Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).
Investigational
Tigilanol tiglate
Investigational
Aeruginosin 98-B
Experimental
scAAV9.U7.ACCA
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
Experimental
Lancovutide
Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics. Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of...
Investigational
Matched Description: … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is …
CIGB 2020 Vaccine
CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate...
Investigational
Matched Description: … trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 …
GRAd-COV2
GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423]. This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2)[L30420, L30423]. Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses .
Investigational
Matched Description: … GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423]. …
Recombinant Bacterial ACE2 Receptors-like Enzyme
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Investigational
Clazakizumab
Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
Pegbelfermin
Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
Investigational
Yttrium Y-90 Labetuzumab
Investigational
Elinzanetant
Elinzanetant is under investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and How Safe It Is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)).
Investigational
Cimlanod
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Branebrutinib
Branebrutinib is under investigation in clinical trial NCT02705989 (Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects).
Investigational
9,10-Deepithio-9,10-Didehydroacanthifolicin
A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)
Experimental
Displaying drugs 1501 - 1525 of 2271 in total